Loading…
Loading…
ZYME does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ZYME and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ZYME and 80,000+ other tickers.
See exactly how ZYME's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ZYME and 80,000+ other tickers.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in…
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,754 shares of the company's stock after buying an additional 147,230 shares during the period. Bank
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 397,190 shares of the company's stock, valued at approximately $10,383,000. Deutsche Bank AG owned approximately 0.54% of
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.